Search

Insulet Announces FDA Clearance of Omnipod GO™, Basal-Only Insulin Pod

Nov 16, 2023
Insulet Corporation
Insulet Corporation has announced the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The newest addition to the Omnipod brand features a tubeless and waterproof Pod which is offered in seven different pre-programmed daily rates, ranging from 10 to 40 units per day, and operates without the need for a handheld device to control the Pod. The product was developed as an alternative to daily injections. Insulet plans to commercialize Omnipod GO in the United States in 2024.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the FDA clearance of its latest innovation, Omnipod GO™, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.

Omnipod GO™ (Photo: Business Wire)

Omnipod GO™ (Photo: Business Wire)

“Omnipod GO was designed to serve the more than three million people using basal insulin or transitioning to insulin therapy to treat their type 2 diabetes,” said Jim Hollingshead, President and Chief Executive Officer. “Our goal is to help people with type 2 diabetes successfully shift to insulin therapy with a product that fundamentally changes how they feel about diabetes management. We’re excited to bring this new solution to market and deliver on our mission to simplify life for people with diabetes.”

Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The newest addition to the Omnipod brand features a tubeless and waterproof* Pod which is offered in seven different pre-programmed daily rates, ranging from 10 to 40 units per day, and operates without the need for a handheld device to control the Pod. It has been cleared for use with the following U-100 insulins: NovoLog®, Fiasp®, Humalog®, Admelog®, and Lyumjev®.

The product was developed to serve people with type 2 diabetes earlier in their treatment journey by starting them on Pod therapy for their insulin delivery, rather than daily injections. If a patient becomes insulin-intensive, meaning they require both basal and bolus insulin, the transition to another Omnipod product would be seamless.

Insulet developed Omnipod GO with convenience in mind for both the primary care physician and the user, including prescribing, getting started, training and using the product. Customers may start Omnipod GO in their physician’s office and will be able to access ongoing supplies through their pharmacy benefit.

Insulet plans to commercialize Omnipod GO in the United States in 2024.

*The Pod has an IP28 rating for up to 25 feet for 60 minutes.

The Danatech Digest

Join 18,000+ professionals who get our latest diabetes technology updates

    

DISCLAIMERS: 

This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit the ADCES finder tool.

ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.

Our Sponsors